Animal Model Market Analysis

Animal Model Market Analysis

By animal type, the animal model market is classified into mice, rats, fish, birds, cattle’s, pigs, amphibians, guinea pigs, dogs, cats, rabbits, monkey’s, sheep, hamsters, and other animal types. The mice segment dominated the market in 2022 with approximately 49.2% business share. Mice model is amongst the most common animal model used in studying human disease and human health. High phylogenetic similarities and physiological relatedness to humans, low maintenance, ease of breeding them in the laboratory, and easy availability of a number of inbred strains make mice models most predominantly used for research of human biology and disease.

Further, mice have a relatively short reproductive cycle and lifespan. This characteristic enables researchers to study multiple generations of mice in a relatively short period. Thus, several advantages offered by mice animal model is set to drive the segment trends.

To get key market trends

  Download Free Sample

Based on technology, the animal model market is segmented into CRISPR, microinjection, embryonic stem cell injection, nuclear transfer and other technologies. The CRISPR technology segment is anticipated to witness high growth at a CAGR of 7.3% during the forecast timeframe. The CRISPR technology has accelerated the development of transgenic animals, demonstrating an unprecedented efficiency and easy replicability, thereby limiting the time and expenses for genome editing. This technology has further enabled the production of animal models with more comprehensive genetic modifications as compared to conventional gene-targeting methods. Genome editing approach based on CRISPR system enables the accurate introduction of mutations at target DNA sequences. This technology has fuelled the generation of animal models and significantly contributed to their increased adoption for research purposes.

Based on application, the animal model market is segmented into research & development, production & quality control, academics, preclinical applications and other applications. The research & development segment held majority market share in 2022 and is expected to witness notable growth to reach USD 22.1 billion by 2032. The increasing number of research & development projects and rise in the investments to develop novel therapeutics is set to drive the segment share. Animal models are used to feature some of the earliest developments related with the disease and to detect potential drug targets.

Further, the pharmacokinetic and pharmacodynamic experiments are conducted for evaluating gastrointestinal absorption, distribution, metabolism, and drug excretion (ADME) parameters for every drug candidate. Animal models are extensively employed in these ADME studies that aid in screening these drug candidates to move forward to the next step in safety and efficacy studies.

Based on use, the animal model market is segmented into human and veterinary. The human segment accounted for largest revenue share in 2022 and is anticipated to grow at significant 7.0% growth rate during the analysis period. This significant segmental revenue is majorly attributed to the increasing prevalence of chronic disorders such as cancer in humans and increasing demand for personalized medicine. According to the World Health Organization (WHO), in 2020, cancer is amongst the critical conditions inflicting substantial disease burden, accounting for approximately 10 million deaths.

Similarly, as per the Cancer Statistics, in 2020, around 1.8 million new cancer cases were diagnosed in the U.S. alone. Therefore, the rise in the prevalence of such chronic human ailments is set to foster the demand for novel therapeutics and effective drugs. This demand in turn is expected to push the use of animal models in drug research & development, thereby propelling the segment outlook.

Based on end-use, the animal model market is segmented into companies, organizations, academic & research institutes and CRO’s. Companies segment accounted for highest segment share in 2022. Heavy investment in research and development by pharmaceutical & biotechnology companies and the surged usage of animal models in these activities is expected to fuel the segment expansion. According to a report by Johnson & Johnson, in 2019, the R&D spending surged by 5% and the major 11 pharma companies accounted for a total of USD 77.6 billion. Thus, animal models are regarded as an essential tool to aid in making the decision to develop potential therapies from preclinical studies to human trials. The rise in the investment and increased demand for effective therapeutics is set to drive the acceptance of animal models.

North America animal model market is projected to expand at 7.1% growth rate over the analysis timeframe. This is due to increasing investments and high number of clinical trials conducted in the region. The region is marked by the presence of major players operating in the mice model market which positively influences the market growth. Further, growing biomedical research in the U.S., and rising preclinical activities by contract research organizations (CROs) and pharmaceutical companies in the region will accelerate the market share. Thus, the rising number of clinical trials and significant investments into these studies is expected to boost the regional market size.